Results 221 to 230 of about 7,284,024 (312)

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Risk of very serious injuries in Swedish scaffolders - What is an acceptable risk? [PDF]

Inj Epidemiol
Järvholm B, Pettersson H.
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Inequities Uncovered: Examining Exclusion in Indian Health Insurance Policies. [PDF]

Healthcare (Basel)
Jain D.
europepmc   +1 more source

Financial toxicity and distress among prostate cancer patients in Lebanon: a cross-sectional study. [PDF]

Front Public Health
Abi Karam M, Mina A, Ghadban E, Azar Z, Khalil J, El Khoury G, El Breidy S, El Hachem C, Saad R, Kassis A, El Khoury R.   +10 more
europepmc   +1 more source

Annual report / Northern Life Insurance 1991

, 2011
Northern Life Insurance
core  

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Immigrants' Gendered Remittance-Sending Patterns and Purposes: The Role of Marital Status. [PDF]

Can Rev Sociol
Dicks H, Kaida L, Swiss L.
europepmc   +1 more source

Annual report / Northern Life Insurance 1987

, 2011
Northern Life Insurance
core  

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source